



CORGENIX REPORTS RECORD SALES FOR FISCAL 2007

- Sales increase 11% year over year

- AspirinWorks® Test Kit receives FDA clearance

- IgG Anti-AtherOx™ Test Kit pre-market notification submitted to FDA

DENVER, Colo. — September 14, 2007 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide marketer of diagnostic test kits, reported record sales of \$7,367,933 for the fiscal year ended June 30, 2007 compared to \$6,635,779 in the fiscal year ended June 30, 2006, an increase of 11%.

“I would rate this as the best year thus far in the company’s history,” said Douglass Simpson, Corgenix’s President and Chief Executive Officer. “We’re proud of our achievements and very excited about our prospects for significant growth in the upcoming first fiscal quarter ending September 30, 2007 and in the remainder of the 2008 fiscal year.”

With many one-time charges, especially during the first six months ended December 31, 2006, the 2007 fiscal year produced an operating loss of \$858,104, compared with operating income of \$335,117 for the prior fiscal year. The net loss for the 2007 fiscal year was \$2,440,573, or \$0.20 per share, compared with a net loss of \$1,586,412, or \$0.41 per share, for the prior fiscal year.

The net loss incurred during the 2007 fiscal year included a substantial increase in operating expenses, much of which were non-recurring expenditures due to the Company's headquarter relocation in July 2006, in addition to significant non-operating and non-cash charges to interest expense attributable to the two 2005 convertible debt financings.

On June 4, 2007, the Company announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AspirinWorks® Test Kit, the Company’s newest diagnostic product. The kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B₂ (11dhTxB₂) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.

More than one million Americans experience heart attacks each year. At risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy’s effect. The AspirinWorks test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.

In addition, Corgenix submitted a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for the Company’s IgG Anti-AtherOx™ Test Kit. This new laboratory test uses the Company’s patented AtherOx technology to detect IgG

antibodies to complexes formed by oxidized low density lipoprotein (oxLDL) with beta-2-glycoprotein I (B2GPI) in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders. Recently published research data shows the association of antibodies to the AtherOx complex with vascular thrombosis (particularly arterial thrombosis) in patients with autoimmune diseases.

“We have made tremendous progress in moving several of our key products closer to market in the U.S. and internationally. We’ve also prepared ourselves logistically for expected significant worldwide growth with our recent expansion into new, state-of-the-art facilities,” said Simpson. “We expect to see meaningful sales of AspirinWorks commencing in the third fiscal quarter beginning in January as more and more laboratories in the U.S. come on line. The continued growth of our other 51 core products is also extremely gratifying.”

Simpson anticipates another record year in sales in fiscal 2008 and further explained that the company’s main goal is also to achieve bottom-line profitability this fiscal year, with a further goal of consistent and greater profitability commencing in fiscal 2009.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Company Contact:

Corgenix Medical Corp

William Critchfield, Senior VP and CFO

(303) 453-8903

Email: wcritchfield@corgenix.com

Media Relations Contact:

Armada Medical Marketing

Dan Snyders, (303) 623-1190 x 230

Fax: (303) 623-1191

Email: dan@armadamedical.com

Condensed Statements of Operations
(in thousands, except per share amounts)

	Fiscal Year Ended	
	June 30, 2007 (audited)	June 30, 2006 (audited)
Net sales	\$ 7,368	\$ 6,636
Gross profit	4,539	4,174
Operating income (loss)	335	335
Net loss	\$ (2,441)	\$ (1,586)
Accretion of discount on redeemable common stock	-	-
Imputed dividend on convertible preferred stock	-	2,280
Net loss attributable to common Shareholders	\$ (2,441)	\$ (3,866)
Basic and diluted (loss) per share	\$ (0.20)	\$ (0.41)
Basic and Diluted shares outstanding	12,467,479	9,482,559

SUMMARY BALANCE SHEET DATA
(in thousands)

	June 30, 2007	June 30, 2006
Cash	\$ 1,324	\$ 3,118
Working capital	2,070	4,205
Total assets	8,889	8,214
Total liabilities	5,646	3,272
Total stockholders' equity	2,993	4,691